Femasys Inc.
FEMY
Positions held
Your positionsFEMY isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $17.13M | Enterprise value | $20.47M | Trailing P/E | — | Forward P/E | -0.96 |
| PEG | — | Price / book | 1.53 | Beta | -2.16 | Dividend yield | 0.00% |
| Revenue growth | -18.9% | Earnings growth | — | Gross margin | 60.9% | Operating margin | -15.3% |
| Profit margin | 0.0% | ROE | -4.2% | ROA | -84.2% | Debt / equity | 1.19 |
| Current ratio | 2.14 | Free cash flow | -$11.23M | Analyst recommendation | none | Mean target | $14.33 |
| 52w high | $22.20 | 52w low | $1.94 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | $0.4M | $0.8M | $0.7M | $0.4M | — |
| Op margin | -1526.7% | -994.0% | -568.3% | -500.9% | -941.1% | — |
| Net income | -$4.5M | $0.8M | -$4.0M | -$4.2M | -$4.6M | — |
| Gross margin | 57.1% | 62.7% | 62.7% | 59.7% | 61.4% | — |
| Gross profit | $0.2M | $0.3M | $0.5M | $0.4M | $0.3M | — |
| Operating income | -$5.1M | -$4.2M | -$4.6M | -$3.7M | -$3.9M | — |
- Revenue -22% vs prior quarter ($0.3M vs $0.4M).
- Gross margin 57.1% (was 62.7% prior quarter).
- Operating margin compressed to -1526.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.3M | $1.6M | $1.1M | $1.2M | — |
| Op margin | -767.0% | -1091.8% | -1353.4% | -961.7% | — |
| Net income | -$18.6M | -$18.8M | -$14.2M | -$11.4M | — |
| Gross margin | 62.0% | 66.6% | 64.5% | 63.4% | — |
| Gross profit | $1.4M | $1.1M | $0.7M | $0.8M | — |
| Operating income | -$17.6M | -$17.8M | -$14.5M | -$11.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands
2026-10-08 · Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
2026-09-15 · Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
2026-09-09 · Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
2026-08-19 · Femasys Secures FDA Pathway for Non-Surgical Contraceptive
2026-08-19 · Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc
2026-08-19 · Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
2026-08-14 · Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
2026-08-12 · Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
2026-08-07 · Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Price (daily)
Full chart · RSI · MACD · patterns